(S)-(+)-2,2-Dimethylcyclopropane Carboxamide

We are (S)-(+)-2,2-Dimethylcyclopropane Carboxamide CAS:75885-58-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

CAS No: 75885-58-4
Product Name: (S)-(+)-2,2-Dimethylcyclopropane Carboxamide
Other Name:
(S)-(+)-2,2-Dimethylcyclopropane Carboxamide
(1S)-2,2-Dimethylcyclopropanecarboxamide
(1S)-2,2-dimethylcyclopropane-1-carboxamide
 
Density: 1.0±0.1 g/cm3
Boiling Point: 225.1±7.0 °C at 760 mmHg
Melting Point: 135-137ºC
Molecular Formula: C6H11NO
Molecular Weight: 113.158
Flash Point: 89.9±18.2 °C
Exact Mass: 113.084061
PSA: 43.09000
LogP: 0.17
Vapour Pressure: 0.1±0.4 mmHg at 25°C
Index of Refraction: 1.480
 
Specification
Appearance: White crystal powder
Assay (GC): ≥99.0%
Chiral content (GC): ≥99.0%
Transmittance: ≥90.0%
Specific rotation: +81.0 – +83.0°
Water: ≤0.5%
Sulphate ash: ≤0.2%
 
Application
Intermediates of Cilastatin CAS: 82009-34-5.
Be used as pharmaceutical intermediate, mainly used to synthesize antibacterial Cilastatin.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

(S)-(+)-2,2-Dimethylcyclopropane Carboxamide


Related News: At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth.L-Aspartic Acid In addition, due to the complex process of changing the API supplier and the risk of uncertainty, the viscosity of pharmaceutical and specialty API companies is usually better.2-bromo-2-metilpropano CAS:507-19-7 Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity.ÁCIDO BENZOICO 2-FLUORO-3- (TRIFLUOROMETHYL) CAS:115029-22-6 Further research on Oligomannate’s pharmacological mechanism and long-term safety and effectiveness is required, according to the NMPA statement.The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.

Related Products
Product Name
1,2-Propanediol View Details
3′,5′-Difluoroacetophenone View Details
1-Methyl-3-phenoxybenzene View Details
5-Methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid manufacturer Benzenesulfonyl Chloride manufacturer 2-Fluoro-5-iodobenzonitrile manufacturer 3,5-Difluorobenzonitrile manufacturer Tripeptide-3 manufacturer